A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a first in man study to determine if [203Pb]VMT-α-NET identifies neuroendocrine
tumors with SPECT/CT. This is the first step to testing [212Pb]-based alpha radiation therapy
in neuroendocrine therapy.
Phase:
Early Phase 1
Details
Lead Sponsor:
Yusuf Menda
Collaborators:
Holden Comprehensive Cancer Center National Cancer Institute (NCI) Viewpoint Molecular Targeting